ストックスクリーナーアプリを入手
29.17
0.65%
-0.19
プレマーケット:
29.00
-0.17
-0.58%
前日終値:
$29.36
開ける：
$29.46
24時間の取引高:
553.95K
Relative Volume:
0.36
時価総額：
$4.05B
収益：
$10.12M
当期純損益:
$-280.49M
株価収益率:
-10.09
EPS:
-2.89
ネットキャッシュフロー:
$-188.51M
1週間 パフォーマンス:
-2.21%
1か月 パフォーマンス:
-15.23%
6か月 パフォーマンス:
-4.36%
1年 パフォーマンス:
-21.61%
1日の値動き範囲:
$28.74
$29.70
1週間の範囲:
$27.70
$30.52
52週間の値動き範囲:
$21.51
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
名前
Avidity Biosciences Inc
セクター
電話
858-401-7900
住所
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
RNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
29.17 | 4.05B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-11 | 開始されました | Raymond James | Strong Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-20 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-09-24 | 開始されました | Goldman | Buy |
| 2024-08-28 | 開始されました | Barclays | Overweight |
| 2024-05-03 | 開始されました | BofA Securities | Buy |
| 2024-03-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-05-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-03-31 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Strong Buy |
| 2021-09-07 | 開始されました | Evercore ISI | Outperform |
| 2021-06-17 | 開始されました | Needham | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-07-07 | 開始されました | Cowen | Outperform |
| 2020-07-07 | 開始されました | Credit Suisse | Outperform |
| 2020-07-07 | 開始されました | SVB Leerink | Outperform |
| 2020-07-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Avidity Biosciences Inc (RNA) 最新ニュース
Avidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027 - Investing.com
Wolfe Research Initiates Coverage on Avidity Biosciences (RNA) with 'Outperform' Rating | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotec - GuruFocus
Why Avidity Biosciences Shares Are Under the Spotlight - TipRanks
Wolfe Research Initiates Coverage on Avidity Biosciences With Outperform Rating, $55 Price Target - MarketScreener
Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotech Advancements | RNA Stock News - GuruFocus
(RNA) Proactive Strategies - news.stocktradersdaily.com
Avidity Biosciences (RNA) Receives Outperform Rating from Wolfe Research | RNA Stock News - GuruFocus
The week in pharma: action, reaction and insight – week to June 13 - The Pharma Letter
Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential - Investing.com Australia
Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential By Investing.com - Investing.com South Africa
Avidity Biosciences chief scientific officer sells $657,694 in stock - Investing.com Australia
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James - MSN
Avidity Biosciences chief scientific officer sells $657,694 in stock By Investing.com - Investing.com South Africa
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
Avidity Biosciences (RNA) Receives Strong Buy Rating from Raymond James | RNA Stock News - GuruFocus
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress – Company AnnouncementFT.com - Financial Times
Raymond James Initiates Coverage of Avidity Biosciences (RNA) with Strong Buy Recommendation - MSN
Avidity Biosciences holds annual stockholders meeting By Investing.com - Investing.com South Africa
Avidity Biosciences Holds 2025 Annual Stockholder Meeting - TipRanks
Avidity Biosciences holds annual stockholders meeting - Investing.com
Avidity Biosciences price target raised to $75 from $65 at Chardan - Yahoo Finance
JP Morgan Raises Price Target for Avidity Biosciences (RNA) to $59 | RNA Stock News - GuruFocus
The Analyst Verdict: Avidity Biosciences In The Eyes Of 12 Experts - Nasdaq
Avidity Biosciences (RNA) Sees Price Target Increase Amid Promis - GuruFocus
Avidity Biosciences (RNA) Gains Boost with New Price Target and Accelerated Approval Path | RNA Stock News - GuruFocus
Barclays Raises Target Price for Avidity Biosciences (RNA) | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Price Target Raised Amid Positive Deve - GuruFocus
RNA: Avidity Biosciences Maintains Buy Rating with Price Target Increase | RNA Stock News - GuruFocus
Avidity reports promising FSHD therapy trial results By Investing.com - Investing.com South Africa
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD - StreetInsider
Avidity Biosciences (RNA) Seeks Accelerated Approval for Key Drug | RNA Stock News - GuruFocus
Avidity Biosciences stock falls following positive trial data By Investing.com - Investing.com Canada
Avidity Biosciences stock falls following positive trial data - Investing.com
BofA lifts Avidity Biosciences stock target to $54 By Investing.com - Investing.com Canada
Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial - Yahoo
Avidity Biosciences (RNA) Price Target Raised Amid Positive Developments | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Receives Enhanced Price Target Followi - GuruFocus
Transcript : Avidity Biosciences, Inc.Shareholder/Analyst Call - MarketScreener
Avidity Biosciences (RNA) Receives Enhanced Price Target Following Trial Results | RNA Stock News - GuruFocus
Avidity Biosciences Shares Face Turbulence Amid Mixed Signals - TipRanks
Avidity Biosciences (RNA) Reports Promising Results from FSHD Treatment Study | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Advances Del-brax Approval Pathway for FSHD Treatment | RNA Stock News - GuruFocus
Avidity Reports Positive Phase 1/2 Data For Del-Brax In FSHD Patients - MarketScreener
Avidity reports promising FSHD therapy trial results - Investing.com
Breakthrough FSHD Drug Trial Success: First-Ever Treatment Shows Multiple Improvements in Muscle Disease - Stock Titan
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD – Company Announcement - Financial Times
Stocks Flashing Renewed Technical Strength: Avidity Biosciences - Investor's Business Daily
(RNA) Investment Analysis - news.stocktradersdaily.com
Avidity Biosciences’ SWOT analysis: innovative muscle therapy stock faces hurdles - Investing.com Nigeria
Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com
Avidity Biosciences Inc (RNA) 財務データ
収益
当期純利益
現金流量
EPS
0.68%
0.50%
大文字化:
|
ボリューム (24 時間):